. 2019 Dec 6;2019(1):482–489. doi: 10.1182/hematology.2019000070

Table 2.

Key data establishing the association of posttreatment MRD and clinical outcome

Study	Study treatment	Method, threshold, sample source	Patients with MRD testing	% uMRD	PFS outcome according to MRD
Kovacs et al 2016⁴¹	FC, FCR, or BR	Flow, 10⁻⁴, pB	CR: 225	CR: 83	CR: median PFS: 61 (uMRD) vs 35 (MRD+) mo
Kovacs et al 2016⁴¹	FC, FCR, or BR	Flow, 10⁻⁴, pB	PR: 329	PR 49	PR: median PFS: 54 (uMRD) vs 21 (MRD+) mo
Krämer et al 2017⁵²	Allo-HCT	Flow, 10⁻⁴, BM	39	69	10-y relapse risk
Krämer et al 2017⁵²	Allo-HCT	Flow, 10⁻⁴, BM	39	69	25% (uMRD) vs 80% (MRD+)
Fraser et al 2019¹²	Ibrutinib plus BR	Flow, 10⁻⁴, pB/BM	289	18	2-y PFS
Fraser et al 2019¹²	Ibrutinib plus BR	Flow, 10⁻⁴, pB/BM	289	18	91.5% (uMRD) vs 75.0% (MRD+)
Stilgenbauer et al 2018²¹	Venetoclax	Flow, 10⁻⁴, pB	101	30	2-y PFS
Stilgenbauer et al 2018²¹	Venetoclax	Flow, 10⁻⁴, pB	101	30	92.8% (uMRD) vs 84.3% (MRD intermediate) vs 63.2% (MRD high)
Kater et al 2019²³	Venetoclax + rituximab	ASO-PCR and flow, 10⁻⁴, pB/BM	180	62^*	3-y PFS
Kater et al 2019²³	Venetoclax + rituximab	ASO-PCR and flow, 10⁻⁴, pB/BM	180	62^*	Only 2% of 83 with uMRD had progressed^†

ASO-PCR, allele specific oligonucleotide polymerase chain reaction; CR, complete response; PR, partial response.

MRD measured at the end of combination therapy (venetoclax + rituximab) after 7 to 9 months, with ongoing venetoclax therapy for 24 months.

^†

13 patients were lost during follow-up.